## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /V8/

		JH U TOO.				SHE	ET	1	OF	4
Form PTO 1449	13	U.S. DEPARTMEN	T OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.					
Form PTO 1449  U.S. DEPARTMENT OF COMMERCE PARTMENT OF COMMERCE PARTMENT AND TRADEMARK OFFICE			241331US20	10/650,799						
				APPLICANT						
LIST OF	REFE	RENCES CITED BY A	PPLICANT	Patricia B. HOYER, et al.						
				FILING DATE	GROUP					
				August 29, 2003	1632					
				U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	IF A	ILIN	IG DAT	E ATE
	AA	6,107,540	08/22/00	Sawyer et al						
	AB	6,583,334	06/24/03	Haslam						
	AC									
	AD		ļ							
	AE									
	AF				<u> </u>					
	AG				<u> </u>					
	AH									
	AI									
	AJ									
	AK		ļ							
	AL				ļ					
	AM									
	AIN	L	<del></del>	<u> </u>	L					
			FO	REIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	· COUNTRY	TRANSL YES		LATION NO			
	AO									
	AP									
	AQ									
	AR									
	AS									
	AT									
	AU									
	ΑV									
		OTHER R	EFERENCES (	Including Author, Title, Date, Pertinent	Pages, et	tc.)				
	AW	Miriam J.J. de Kleijn e American Journal of B	et al.; "Endogen Epidemiology, V	ous Estrogen Exposure and Cardivascul ol. 155, No. 4, pp. 339-345; 2002	ar Mortality	Risk in Po	stmend	pau	sal Wo	men";
	AX	Caren G. Solomon et al.; "Menstrual Cycle Irregularity and Risk for Future Cardivascular Disease"; The Journal of Clinical Endocrinology & Metabolism, 87(5), pp. 2013-2017; 2002								
	AY	Frank B. Hu, MD et al.; "Age at Natural Menopause and Risk of Cardivascular Disease", Arch Intern Med/Vol 159, pp. 1061-1066; May 24, 1999								
	AZ	Francine Grodstein et al: "A Prospective, Observational Study of Postmenopousual Hormone Therapy and Primary Prevalion of Cardiovascular Disease", Annals of Internal Medicine, Vol. 133, No. 12, pp. 933-941; December 19, 2000					ached			
xaminer	1	Valarie Bertoglio/			Date Con	Date Considered 07/13/2009				

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

					SHEET	2	OF	4	
(Modified) PATENT AND TRADEMARK OFFICE		U.S. OEPARTMENT OF COMMERCE	ATTY DOCKET NO.		SERIAL NO.				
		PATENT AND HOLDEMARK OFFICE	241331US20	10/650,799					
LIST OF	F REFEI	RENCES CITED BY APPLICANT	APPLICANT Patricia E	B HOYER	₹, et al.				
RENCES CO	ONSIDE	ERED EXCEPT WHERE LINED THRO	FILING DATE UGH. /VB/ August 29, 2003		GROUP 1632				
		OTHER REFERENCES (	Including Author, Title, Date, Pertinen	nt Pages, e	L				
	AAA	Francine Grodstein et al; "Postmenop Health Study"; Annals of Internal Med	pausal Homnone Use and Secondary Prevention of Coronary Events in the Nurses' dicine; Vol. 135, No. 1, pp. 1-8; July 3, 2001						
	AAB	Evidence"; The American Journal of	ausal Hormone Therapy and the Risk of Cardiology; Vol. 90(1A), pp. 26F-29F; Ju	uly 3, 2002				ogic	
	AAC	NIH: Postmenopausal Hormone Therapy Information; http://www.nih.gov/PHTindex.htm; 4pp. 07/26/2003							
	AAD	Karin H. Humphries et al; "Risks and benefits of hormone replacement therapy: The evidence speaks", Canadian Medical Association, 168(8), pp. 1001-1010; April 15, 2003							
	AAE	Gail A. Laughlin et al; "Hysterectorny, Oophorectomy, and Endogenous Sex Hormone Levels in Older Women: The Rancho Bemardo Study"; The Journal of Clinical Endocrinology & Metabolism"; Vol. 85, No. 2, pp. 645-651; 2000							
	AAF	Manuel Neves-e-Castro et al: "Results from WHI and HERS II - Implications for Women and the prescriber of HRT"; Maturitas 42 (2002) 255-256							
	AAG	Bjarne K. Jacobsen et al "Age at Natural Menopause and All-Cause Mortality. A 37-Year Follow-up of 19/731 Norwegian Women"; American Journal of Epidemiology, Vol. 157, No. 10, pp. 923-929, 2003							
	аан	Sally A. Shumaker, Ph.D. et al. "Estrogen Plus Progesiin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women The Women's Health Initiative Memory Study: A Randomized Controlled Trial"; JAMA, Vol. 269, No. 20 (Reprinted), pp. 2651-2662; May 28, 2003							
	AAI	Peter P, Zandl, Ph.D. et al.; "Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women The Cache County Study"; JAMA, Vol. 288, No. 17, pp. 2123-2129; November 6, 2002							
	LAA	Susan M. Fontaine et al; 'Stereochemical Aspects of Viryleydohene Bloactivation in Rodent Hepatic Microsomes and Punified Human Cytochrome P450 Enzyme Systems'; DMD, Vol. 29, No. 2, pp. 179-184; 2001							
	AAK	S.M. Borman et al; 'Ovoloxidity in Female Fischer Rats and 86 Mice Induced by Low-Dose Exposure to Three Polycyclic Aromatic Hydrocarbons: Comparison through Calculation of an Ovoloxic Index', Toxicology and Applied Pharmacology, Vol. 167, pp. 191-198; 2000							
	AAL	Patricia B Hoyer et al; "Ovarian Toxicity of 4-Vinylcyclohexene Diepoxide: A Mechanistic Model"; Toxicologic Pathology, Vol. 29, No. 1, pp. 91-99; 2001							
	ААМ	Patricia B. Hoyer et al: "Assessment of Follicle Desruction in Chemical-Induced Ovarian Toxicity"; Annu. Rev. Pharmacol. Toxicol., Vol. 36, pp. 307-331; 1996							
	AAN	Loretta P. Mayer et al; "Long-term effects of ovarian follicular depletion in rats by 4-vinylcyclohexene diepoxide"; Reproductive Toxicology, Vol. 16, pp. 775-781; 2002							
	AAO	Stephen B. Hooser et al; "Long-Term Ovarian and Gonadotropin Changes in Mice Exposed to 4-Vinylcyclohexene"; Reproductive Toxicology, Vol. 8, No. 4, pp. 315-323; 1994							
	í l	Bill J. Smith et al: "The Role of Epoxidation in 4-Vinylcydohexene-Induced Ovarian Toxicity"; Toxicology and Applied Pharmacology, Vol. 105, pp. 372-381; 1990							
	AAQ								
Examiner		/Valarie Bertoglio/		Date Cons	sidered	07/1	12/2009		
*Examiner: In	nitial if re	_	citation is in conformance with MPEP 6( with next communication to applicant.				13/2009 ot in		

			SHE	E1 3 OF 4			
Form PTO 1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL N	10.			
(Modified)	PATENT AND TRADEMARK OFFICE	241331US20		10/650,799			
	EDENIOSO OITED BY 100115	APPLICANT					
LIST OF REF	ERENCES CITED BY APPLICANT	Patricia E	HOYER, et al.				
ALL REFERENCES CONSIDERED EXCEPT WHERE LIN		ED-INARONOGH. /VB/	GROUP	JP			
		August 29, 2003		1632			
	OTHER REFERENCES (	Including Author, Title, Date, Pertinen	t Pages, etc.)				
AAA	P.J. Devine et al; "Ultrastructural Evaluation of Oocytes During Atresia in Rat Ovarian Follicles"; Biology of Reproduction, Vol. 63, pp. 1245-1252; 2000						
AAE	Xiaming Hu et al; "Expression and Redistribution of Cellular Bad, Bax and Bci-X, Protein Is Associated with VCD-Induced Ovoloxicity in Rats" Biology of Reproduction, Vol. 65, pp. 1489-1495; 2001						
AAG	Xiaoming Hu et al; "Apoptosis Induced in Rats by 4-Vinylcyclohexene Diepoxide is Associated with Activation of Caspase Cascades"; Biology of Reporduction, Vol. 65, pp. 87-93; 2001						
AAL	Xiaoming Hu et al; "Activation of Milogen-Activated Protein Kinases and AP-1 Transcription Factor in Ovotoxicity Induced by 4-Vinylcyclohexene Diepoxide in Rats <sup>1*</sup> ; Biology of Reproduction, Vol. 67, pp. 718-724; 2002						
AAH	S.M. Borman et al; "Single Dose of the Follicles"; Toxicology and Applied Ph	S.M. Borman et al, "Single Dose of the Ovotoxicant 4-Vinylcydohexene Diepoxide Is Protective in Rat Primary Ovarian Follicles", Toxicology and Applied Pharmacology, Vol. 158, pp. 244-252; 1999					
AAF	Kary E. Tohmpson et al; "17β-Estradiol Affords Protection against 4-Vinylcyclohexene Diepoxide-Induced Ovarian Foliicie Loss in Fischer-344 Rats"; Endocrinology, 143(3), pp. 1058-1065; March 2002						
AAC	Lori Mosca, MD et al; "Cardiovascular Disease in Women A Statemtn for Healthcare Professionals From the American Heart Association"; Circulation, Vol. 96, No. 7, pp. 2468-2482; October 7, 1997						
AAH	Suzanne Oparii; Supplement to Hype Journal of the American Heart Assoc	ertension; Arthur C. Corcoran Memorial L iation, Vol. 33, No. 1, Part II; January 199	ecture; "Hormones an 99	d Vasoprotection";			
AAI	Stephen Hulley, MD et al; "Randomiz Disease in Postmenopausal Women"	ed Trial of Estrogen Plus Progestin for S ; JAMA, Vol. 280, No. 7, pp. 605-613; Au	econdary Prevention of ugust 19, 1998	of Coronary Heart			
AAL	Dr. Anderson et al; "Risks and Benefi No. 3, pp. 321-333; July 17, 2002	its of Estrogen Plus Progestin in Healthy	Postmenopausal Wor	men"; JAMA, Vol. 288,			
AAH	David W. Purdie; "Consequences of I 809-823; 2000	long-term hormone replacement therapy	; British Medical Bulle	tin, Vol. 56, No. 3, pp.			
AAL	Carmen Rodriguez, MD, MPH et al; " Study of US Women"; JAMA, Vol. 28:	Estrogen Replacement Therapy and Ova 5, No. 11, pp. 1460-1465; March 21, 200	arlan Cancer Mortality	in a Large Prospective			
AAN	Francis L. Bellino, Ph.D.; "Nonprimate North American Menopause Society,	e Animal Models of Menopause: Worksh Vol. 7, No. 1, pp. 14-24; 2000	iop Report"; Menopau	se: The Journal of the			
AAH	Howard L. Judd, MD; "Hormonal Dynamics Associated with the Menopause"; Clinical Obsterics and Gynecology, Vol. 19, No. 4, pp. 775-788; December 1976						
AAE	Jodi A. Flaws et al; "Destruction of Preantral Follicles in Adult Rats By 4-Vinylcyclohexene Diepoxide"; Reproductive Toxicology, Vol. 8, No. 6, pp. 500-514; 1994						
AAF	Shao-Wen Kao et al; "Early Effects of Reproductive Toxicology, Vol. 13, No	f Ovotoxicity Induced By 4-Vinylcyclohex . 1, pp. 67-75; 1999	ene Diepoxide in Rats	and Mice";			
AAG	Gregory F. Erickson, Menopause Bio	logy and Pathobiology; "Ovarian Anatom	y and Physiology"; Ch	apter 2, pp. 13-31; 2000			
Examiner	/Valarie Bertoglio/		Date Considered	07/13/2009			

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.					
(Modified)	PATENT AND TRADEMARK OFFICE	241331US20	10/650,799					
		APPLICANT						
LIST OF REFE	RENCES CITED BY APPLICANT	Patricia B HOYER, et al.						
		FILING DATE	GROUP					
ALL REFERENCES	CONSIDERED EXCEPT WHERE LIF	NED THROUGHAUGUSt 29, 2003	1632					
	OTHER REFERENCES (	Including Author, Title, Date, Pertinent I	Pages, etc.)					
AAA	Cheryl A. Dyer, Ph.D., Alzeimer's Assisoform effect on perimenopausal ova	sociation, KRS: Application form for Individual arian steroids and risk for AD 2003	lual Research Project, Project Title: Apo E					
AAB	Patricia B. Hoyer, Research Plan, Gr. 2003	ant Application, PHS 398/2590, pp. 17-47.	,					
AAF	Loretta P. Mayer, Grant Proposal, AIM III, p. 25. reviewed 10/19/2007							
	Loretta P. Mayer et al., Preprint of an	article entitled "The Follicle-Depleted Mou	ise Ovary Produces Androgen					
AAD	reviewed 10/19/2007							
AAF	Loretta P. Mayer et al., July 2001 Presentation to the Ottowa Society for Study of Reproduction, "Long-Term Effects of Ovotoxicity in Rats Exposed to 4-Vinylcydohexene Diepoxide.							
AAF	Loretta P. Mayer et al., Abstract and Poster Presentation, "An ovary-intact mouse model that mimics peri-menopause in women", Published after September 20, 2002.							
AAD	L.P. Mayer et al., Abstract and Poster Presentation at the Endocrinology annual meeting in San Francisco, "Development of an Ovary-Intact Murine Model for the Study of Menopause-related Pathologies", June 2002.							
ААН	GM Buss et al., Abstract and Poster Presentation, Presented at the Moutain West Society for Toxicology, September 20, 2001, "Steroidogenic Responsiveness of 4-Vinylcyclohexene Diepoxide (VCD-Induced Follicle-Deplete Murine Ovaries to Gonadotropin Stimulation In Vitro."							
AAI	Hoyer and Mayer, "Background and S	Significance," Unpublished Summary, Marc	ch 2002, pp. 1-7.					
AAL	Loretta P. Mayer et al., Poster Preser American Heart Association, Spring (	ntation at the Atherosclerosis, Thrombosis March?) 2002.	and Vascular Biology Meeting of the					
AAB	In House Talk done By 10/30/01, enti	tled "Mouseopause: A model whose time t	nas come.					
AAL								
ААМ								
AAN								
AAO								
AAF								
AAQ								
Examiner /	'alarie Bertoglio/		Date Considered 07/13/2009					